Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors

NCT00049023 is registered in ClinicalTrials.gov with O'Dorisio, M S as lead sponsor.

NCT NCT00049023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00049023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors
Lead sponsor
O'Dorisio, M S
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2002
Completion date
August 31, 2011
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, gastrointestinal carcinoid tumor, islet cell tumor, neuroblastoma, pheochromocytoma, sarcoma, unspecified childhood solid tumor, protocol specific